Abstract
Prostate cancer remains one of the most common cancers in men and treatment options for patients with advanced or metastatic disease are limited. Immunotherapeutic approaches, such as passive or active immunotherapy, have been shown to be successful in treating some cancer patients. These rely on the identification of cancer specific antigens that can be targeted by the immune system or used to diagnose as early as possible and/or to monitor the disease and its progression. Several prostate cancer antigens have already been identified; these include Prostate-Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), PAGE-4, PSP 94, differential display 3, prostate androgen-regulated transcript 1 and six-transmembrane epithelial antigen prostate-restricted antigens and these represent potential candidate for immunotherapy against prostate cancer. The following review describes the importance of these antigens with a particular emphasis to the PAP antigen and T21, a recently identified prostate cancer associated antigen, as very promising targets for prostate therapy.
Keywords: Prostate, peptides, immunotherapy, SEREX, T21
Current Cancer Therapy Reviews
Title: Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Volume: 4 Issue: 2
Author(s): Amanda K. Miles, Alistair Roger, Richard Parkinson, Robert C. Rees and Stephanie E.B. McArdle
Affiliation:
Keywords: Prostate, peptides, immunotherapy, SEREX, T21
Abstract: Prostate cancer remains one of the most common cancers in men and treatment options for patients with advanced or metastatic disease are limited. Immunotherapeutic approaches, such as passive or active immunotherapy, have been shown to be successful in treating some cancer patients. These rely on the identification of cancer specific antigens that can be targeted by the immune system or used to diagnose as early as possible and/or to monitor the disease and its progression. Several prostate cancer antigens have already been identified; these include Prostate-Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), PAGE-4, PSP 94, differential display 3, prostate androgen-regulated transcript 1 and six-transmembrane epithelial antigen prostate-restricted antigens and these represent potential candidate for immunotherapy against prostate cancer. The following review describes the importance of these antigens with a particular emphasis to the PAP antigen and T21, a recently identified prostate cancer associated antigen, as very promising targets for prostate therapy.
Export Options
About this article
Cite this article as:
Miles K. Amanda, Roger Alistair, Parkinson Richard, Rees C. Robert and McArdle E.B. Stephanie, Overview of Prostate Biomarkers as Potential Targets for Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310034
DOI https://dx.doi.org/10.2174/157339408784310034 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface
Recent Patents on Anti-Cancer Drug Discovery Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Recent Patents on Biotechnology Application of Hyperthermia for Cancer Treatment: Recent Patents Review
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies
Current Pharmaceutical Biotechnology Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs
Current Pharmaceutical Biotechnology Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Further Vitamin D Analogs
Current Vascular Pharmacology Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Current Drug Delivery